Jupiter Topco LLC Purchases New Position in Biogen Inc. $BIIB

Key Points

• Jupiter Topco bought 19,831 Biogen shares during the second quarter, valued at approximately $4.3 million. Institutional investors collectively own 87.93% of Biogen, with BlackRock and Primecap also establishing significant positions.
• Biogen reported quarterly earnings of $3.60 per share, exceeding analysts’ $2.94 estimate, while revenue rose 3.4% year over year to $2.74 billion. The company issued fiscal 2026 EPS guidance of $12.00–$13.00.
• Analyst sentiment remains moderately bullish: Biogen has an average “Moderate Buy” rating and a consensus price target of $227.79, although the stock recently traded down 0.3% at $216.04.

Jupiter Topco LLC purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 19,831 shares of the biotechnology company's stock, valued at approximately $4,284,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Biogen in the second quarter valued at approximately $3,453,878,000. Primecap Management Co. CA purchased a new position in shares of Biogen during the second quarter valued at approximately $3,274,304,000. Geode Capital Management LLC grew its holdings in Biogen by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company's stock worth $736,435,000 after buying an additional 130,618 shares in the last quarter. Norges Bank bought a new stake in Biogen during the fourth quarter worth $464,408,000. Finally, Invesco Ltd. raised its position in Biogen by 4.2% in the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company's stock valued at $338,731,000 after buying an additional 98,001 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen Trading Down 0.3%

Shares of Biogen stock opened at $216.04 on Wednesday. The firm has a market cap of $31.92 billion, a PE ratio of 38.24, a P/E/G ratio of 2.40 and a beta of 0.17. Biogen Inc. has a 1 year low of $133.53 and a 1 year high of $222.85. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The stock has a fifty day moving average price of $208.52 and a 200-day moving average price of $196.06.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts' consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the previous year, the firm earned $5.47 EPS. The firm's quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts anticipate that Biogen Inc. will post 12.39 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BIIB. Truist Financial upgraded Biogen from a "hold" rating to a "buy" rating and raised their price objective for the company from $190.00 to $235.00 in a research note on Monday, July 13th. HC Wainwright upped their target price on shares of Biogen from $237.00 to $251.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Royal Bank Of Canada increased their target price on shares of Biogen from $240.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, August 25th. Bank of America dropped their price target on shares of Biogen from $217.00 to $215.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 21st. Finally, Wedbush boosted their price target on shares of Biogen from $201.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $227.79.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.